134 related articles for article (PubMed ID: 36731894)
1. The value of PET/CT for cytoreductive surgery selection in recurrent ovarian carcinoma.
Nunes RL; Teixeira FR; Diniz TP; Faloppa CC; Mantoan H; da Costa AABA; Baiocchi G
J Gynecol Oncol; 2023 May; 34(3):e31. PubMed ID: 36731894
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic value of integrated ¹⁸F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in recurrent epithelial ovarian cancer: accuracy of patient selection for secondary cytoreduction in 134 patients.
Lee YJ; Kim YM; Jung PS; Lee JJ; Kim JK; Kim YT; Nam JH
J Gynecol Oncol; 2018 May; 29(3):e36. PubMed ID: 29400023
[TBL] [Abstract][Full Text] [Related]
3. The role of F18-FDG PET/CT in predicting secondary optimal de-bulking in patients with recurrent ovarian cancer.
Amit A; Hodes A; Lavie O; Keidar Z; Matanes E; Lowenstein L
Surg Oncol; 2017 Dec; 26(4):347-351. PubMed ID: 29113651
[TBL] [Abstract][Full Text] [Related]
4. Use of (18)F-FDG PET/CT in the preoperative evaluation of patients diagnosed with peritoneal carcinomatosis of ovarian origin, candidates to cytoreduction and hipec. A pending issue.
Lopez-Lopez V; Cascales-Campos PA; Gil J; Frutos L; Andrade RJ; Fuster-Quiñonero M; Feliciangeli E; Gil E; Parrilla P
Eur J Radiol; 2016 Oct; 85(10):1824-1828. PubMed ID: 27666623
[TBL] [Abstract][Full Text] [Related]
5. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial.
Shi T; Zhu J; Feng Y; Tu D; Zhang Y; Zhang P; Jia H; Huang X; Cai Y; Yin S; Jiang R; Tian W; Gao W; Liu J; Yang H; Cheng X; Zang R
Lancet Oncol; 2021 Apr; 22(4):439-449. PubMed ID: 33705695
[TBL] [Abstract][Full Text] [Related]
6. Benefits of fluorine-18 fludeoxyglucose positron emission tomography in secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer.
Peng P; Zhu ZH; Zhong ZJ; Zheng K; Yang JX; Cao DY; Shen K
Br J Radiol; 2015 Aug; 88(1052):20150109. PubMed ID: 25989698
[TBL] [Abstract][Full Text] [Related]
7. A score system for complete cytoreduction in selected recurrent ovarian cancer patients undergoing secondary cytoreductive surgery: predictors- and nomogram-based analyses.
Bogani G; Tagliabue E; Signorelli M; Ditto A; Martinelli F; Chiappa V; Mosca L; Sabatucci I; Leone Roberti Maggiore U; Lorusso D; Raspagliesi F
J Gynecol Oncol; 2018 May; 29(3):e40. PubMed ID: 29533023
[TBL] [Abstract][Full Text] [Related]
8. The value of 18F-FDG PET/CT imaging combined with detection of CA125 and HE4 in the diagnosis of recurrence and metastasis of ovarian cancer.
Sun J; Cui XW; Li YS; Wang SY; Yin Q; Wang XN; Gu L
Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7276-7283. PubMed ID: 32706065
[TBL] [Abstract][Full Text] [Related]
9. Volume-based quantitative FDG PET/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery.
Vargas HA; Burger IA; Goldman DA; Miccò M; Sosa RE; Weber W; Chi DS; Hricak H; Sala E
Eur Radiol; 2015 Nov; 25(11):3348-53. PubMed ID: 25916387
[TBL] [Abstract][Full Text] [Related]
10. A comparative analysis of prediction models for complete gross resection in secondary cytoreductive surgery for ovarian cancer.
Cowan RA; Eriksson AGZ; Jaber SM; Zhou Q; Iasonos A; Zivanovic O; Leitao MM; Abu-Rustum NR; Chi DS; Gardner GJ
Gynecol Oncol; 2017 May; 145(2):230-235. PubMed ID: 28285846
[TBL] [Abstract][Full Text] [Related]
11. Positron Emission Tomography/Computed Tomography in Platinum-sensitive Recurrent Ovarian Cancer: A Single-center Italian Study.
Gadducci A; Simonetti E; Manca G; Guidoccio F; Fanucchi A; Cosio S; Volterrani D
Anticancer Res; 2020 Apr; 40(4):2191-2197. PubMed ID: 32234914
[TBL] [Abstract][Full Text] [Related]
12. Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings.
Chung HH; Kang WJ; Kim JW; Park NH; Song YS; Chung JK; Kang SB; Lee HP
Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):480-6. PubMed ID: 17089122
[TBL] [Abstract][Full Text] [Related]
13. FDG-PET/CT to predict optimal primary cytoreductive surgery in patients with advanced ovarian cancer: preliminary results.
Alessi A; Martinelli F; Padovano B; Serafini G; Lorusso D; Lorenzoni A; Ditto A; Lecce F; Mira M; Donfrancesco C; Raspagliesi F; Crippa F
Tumori; 2016; 102(1):103-7. PubMed ID: 26350201
[TBL] [Abstract][Full Text] [Related]
14. Minimally invasive secondary cytoreduction plus HIPEC for recurrent ovarian cancer: a case series.
Fagotti A; Petrillo M; Costantini B; Fanfani F; Gallotta V; Chiantera V; Turco LC; Bottoni C; Scambia G
Gynecol Oncol; 2014 Feb; 132(2):303-6. PubMed ID: 24378877
[TBL] [Abstract][Full Text] [Related]
15. Preoperative PET/CT score can predict incomplete resection after debulking surgery for advanced serous ovarian cancer better than CT score, MTV, tumor markers and hematological markers.
Wang J; Liu L; Pang H; Liu L; Jing X; Li Y
Acta Obstet Gynecol Scand; 2022 Nov; 101(11):1315-1327. PubMed ID: 35979992
[TBL] [Abstract][Full Text] [Related]
16. Influence of 2-(18F) fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography on recurrent ovarian cancer diagnosis and on selection of patients for secondary cytoreductive surgery.
Risum S; Høgdall C; Markova E; Berthelsen AK; Loft A; Jensen F; Høgdall E; Roed H; Engelholm SA
Int J Gynecol Cancer; 2009 May; 19(4):600-4. PubMed ID: 19509556
[TBL] [Abstract][Full Text] [Related]
17. Role of minimally invasive secondary cytoreduction in patients with recurrent ovarian cancer.
Conte C; Marchetti C; Loverro M; Giudice MT; Rosati A; Gallotta V; Scambia G; Fagotti A
Int J Gynecol Cancer; 2023 Feb; 33(2):137-144. PubMed ID: 36639195
[TBL] [Abstract][Full Text] [Related]
18. External validation of two prediction models of complete secondary cytoreductive surgery in patients with recurrent epithelial ovarian cancer.
van de Laar R; Massuger LF; Van Gorp T; IntHout J; Zusterzeel PL; Kruitwagen RF
Gynecol Oncol; 2015 May; 137(2):210-5. PubMed ID: 25677063
[TBL] [Abstract][Full Text] [Related]
19. Positron emission tomography (PET) and magnetic resonance imaging (MRI) for assessing tumour resectability in advanced epithelial ovarian/fallopian tube/primary peritoneal cancer.
Roze JF; Hoogendam JP; van de Wetering FT; Spijker R; Verleye L; Vlayen J; Veldhuis WB; Scholten RJ; Zweemer RP
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD012567. PubMed ID: 30298516
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of PET-CT imaging versus AGO-scoring in patients planned for cytoreductive surgery in recurrent ovarian cancer.
Lenhard SM; Burges A; Johnson TR; Kirschenhofer A; Bruns C; Linke R; Friese K
Eur J Obstet Gynecol Reprod Biol; 2008 Oct; 140(2):263-8. PubMed ID: 18614272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]